Medication info
Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Empagliflozin/Metformin Extended-Release Tablet 10/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Dark yellow oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501909 · Approved 2025.07.25 · Insurance code 647805930

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse reactions and 6. Interactions). Special populations Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
View approved original text

This medication is used to assist in blood glucose control in adults with type 2 diabetes through the combination of empagliflozin and metformin. It is particularly suitable for patients on diet and exercise regimens, and is administered when blood glucose control is difficult. Additionally, the effects of this medication on the occurrence of cardiovascular events in adults with type 2 diabetes who have cardiovascular disease should be consulted according to professional guidelines. Therefore, it helps in the management of blood glucose and cardiovascular health in diabetic patients with concurrent cardiovascular disease.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with the evening meal. Take one tablet of this medicine 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this medicine 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole without splitting, crushing, grinding, or chewing. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredient of the medicine. If a patient repeatedly reports finding this medicine in their feces, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions for Use, 5. General precautions). ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated but additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. ⦁ Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose appropriately adjusted. ⦁ When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse reactions and 6. Interactions). Special populations Renal impairment Because dosage adjustment is required according to renal function, assessment of renal function is recommended before starting this medicine and periodically during treatment. No dosage adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and have no other condition that may increase the risk of lactic acidosis, this medicine may be used with adjustment of the metformin hydrochloride dose as follows. - The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, discontinue this medicine immediately. Older adults In patients 75 years of age and older, consider renal function and the risk of volume depletion.

Precautions

This medication helps control blood glucose and is used for diabetes treatment. Before taking this medication, renal function must be confirmed to be normal; it should not be used in cases of severe renal impairment. This medication should also not be used in cases of severe infections, dehydration, acute heart problems, or acute illnesses such as sepsis. This medication can cause a rare side effect known as lactic acidosis, which can be life-threatening; if symptoms such as vomiting, abdominal pain, difficulty breathing, or weakness occur, consult a physician immediately. Furthermore, when this medication is used in combination with other diabetes medications, there may be an increased risk of hypoglycemia, so blood glucose changes should be closely monitored. Temporarily discontinue this medication before and after procedures or tests involving iodinated contrast media, and resume only after renal function has fully recovered. This medication may increase the risk of genital infections and urinary tract infections, so treatment should be sought immediately upon the onset of infection symptoms. Elderly patients or those at risk of fluid loss should be particularly cautious of dehydration or hypotension while taking this medication and it is important to regularly monitor renal function. Women who are pregnant, potentially pregnant, or breastfeeding should avoid this medication, and breastfeeding should be discontinued while taking it. This medication should be swallowed whole without breaking or chewing the tablets; while the coating may appear in stools, this is normal. Alcohol consumption should be avoided during treatment, and any concurrent medications should be consulted with a physician or pharmacist due to potential interactions. Symptoms of hypoglycemia, such as dizziness, cold sweat, or trembling, may occur while taking this medication; recognize and respond appropriately to these symptoms. In case of overdose, seek medical attention immediately for appropriate treatment, particularly because of the risk of lactic acidosis requiring prompt action. This medication should be stored safely and kept out of reach of children.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 184 more
  • abnormal liver function tests
  • hepatitis
  • taste disturbances
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated creatinine levels
  • decreased glomerular filtration rate
  • decreased and deficient vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • urosepsis
  • pyelonephritis
  • rash
  • urticaria
  • angioedema
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • intestinal hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • adnexal-ovarian abscess
  • vestibular neuritis
  • acute pyelonephritis
  • headache
  • intracranial aneurysm
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureterolithiasis
  • acute kidney injury
  • ureterolithiasis
  • hematuria
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal drusen
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • phlegm retention
  • cough
  • epistaxis
  • allergic rhinitis
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • diarrhea
  • dyspepsia
  • abdominal pain
  • nausea
  • gastritis
  • gastrointestinal disorder
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent exposure to air or moisture, and maintain the storage temperature between 1 to 30 degrees Celsius. Proper storage can prolong the effectiveness of the medication.

Appearance and packaging

Appearance

Dark yellow oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.